CNC Centene Corp

$41.23

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Centene's upcoming earnings report on October 29th is set against a backdrop of significant market anticipation, particularly as the company navigates a challenging healthcare landscape with an EPS estimate of $0.00. This figure aligns with the whisper number, suggesting that analysts and investors are not expecting surprises in terms of profitability. However, the focus will likely be on Centene's robust revenue estimate of $47.72 billion, which underscores the company's ability to maintain substantial top-line growth despite the zero EPS projection. With a market cap of approximately $17.3 billion, Centene's strategic maneuvers in expanding its Medicaid and Medicare offerings could be pivotal in sustaining its revenue momentum. Investors will be keenly observing how Centene manages its cost structure and operational efficiencies to potentially convert this revenue strength into future earnings growth. As the healthcare sector continues to evolve, Centene's performance in this earnings cycle will be a critical indicator of its adaptability and strategic foresight.

Updated On 1/6/2026

About Centene Corp

Centene Corporation is a large publicly traded company and a multi-line managed care enterprise that serves as a major intermediary for both government-sponsored and privately insured health care programs. It is a healthcare insurer that focuses on managed care for uninsured, underinsured, and low-income individuals.

Website: https://www.centene.com

Sector
FINANCE
Industry
HOSPITAL & MEDICAL SERVICE PLANS
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1071739
Address
7700 FORSYTH BLVD., ST LOUIS, MO, US
Valuation
Market Cap
$30.11B
P/E Ratio
9.62
PEG Ratio
0.66
Price to Book
1.14
Performance
EPS
$6.31
Dividend Yield
Profit Margin
2.25%
ROE
12.60%
Technicals
50D MA
$59.59
200D MA
$65.25
52W High
$80.59
52W Low
$55.03
Fundamentals
Shares Outstanding
496M
Target Price
$79.54
Beta
0.53

CNC EPS Estimates vs Actual

Estimated
Actual

CNC News & Sentiment

Dec 31, 2025 • MarketBeat SOMEWHAT-BULLISH
Ethic Inc. Purchases 35,149 Shares of Centene Corporation $CNC
Ethic Inc. increased its stake in Centene Corporation (NYSE:CNC) by 51.4% during the third quarter, acquiring an additional 35,149 shares. This brings Ethic Inc.'s total holdings in Centene to 103,533 shares, valued at $3.694 million. Other institutional investors also adjusted their positions, and Wall Street analysts currently have a "Hold" rating on the stock with a consensus price target of $38.44.
Dec 31, 2025 • MarketBeat SOMEWHAT-BULLISH
Brookstone Capital Management Sells 8,259 Shares of Elevance Health, Inc. $ELV
Brookstone Capital Management significantly reduced its stake in Elevance Health (NYSE:ELV) by 80.2%, selling 8,259 shares but retaining 2,040 shares valued at $659,000. Elevance Health exceeded Q3 expectations with EPS of $6.03 and revenues of $50.09 billion, while also declaring a quarterly dividend of $1.71. Analysts currently maintain a "Hold" rating for the stock with an average price target of $396.21.
Dec 31, 2025 • The Center Square BEARISH
Three Centene health plans fined $1.7 million by state, health officials say
Three Centene Corporation health plans have been fined $1.7 million by the California Department of Managed Health Care for failing to meet timely access standards for appointments. The fines were levied against Health Net ($1.2 million), Human Affairs International of California ($300,000), and Health Net Community Solutions, Inc. ($200,000). The department emphasized that timely access to care is a legal right, and the fines aim to ensure health plans comply with these standards, with funds directed toward programs supporting underserved areas and healthcare data collection.
Dec 30, 2025 • The Globe and Mail NEUTRAL
Why Humana Deserves Patience Now: Too Early to Buy, Too Risky to Sell
Humana Inc. has faced investor scrutiny due to rising medical costs and Medicare Advantage uncertainties but has shown relative resilience compared to its peers. While near-term buying isn't compelling due to valuation and ongoing pressures, its long-term investment case is supported by its strong market position and demographic tailwinds. Current investors are advised patience, and new investors to monitor cost trends and reimbursement clarity.
Dec 30, 2025 • Stocktwits NEUTRAL
Is Molina Healthcare The Next GEICO? Michael Burry Feels It's A ‘Special One’
Michael Burry, known for "The Big Short," has taken a long position in Molina Healthcare (MOH), likening it to an early-stage GEICO. Despite the company's recent struggles with slowing revenue growth and thin margins, Burry sees Molina as a "special one" with a clearer path to long-term earnings growth than many large-cap peers, even suggesting Warren Buffett would invest in it if he were younger and scaling his insurance investments. Analysts, however, mostly maintain neutral ratings, seeing limited upside for the stock.
Dec 30, 2025 • Benzinga NEUTRAL
Looking Into Centene Corp's Recent Short Interest
Centene Corp's (NYSE: CNC) short interest has decreased by 6.98% since its last report, with 12.59 million shares currently sold short, representing 2.93% of available shares. It would take traders an average of 1.97 days to cover their short positions. Compared to its peers, Centene Corp has less short interest, indicating a potentially more bullish sentiment from investors.
Sentiment Snapshot

Average Sentiment Score:

0.019
50 articles with scored sentiment

Overall Sentiment:

Neutral

CNC Reported Earnings

Jul 25, 2025
Jun 30, 2025 (Pre market)
-0.63 Surprise
  • Reported EPS: $-0.51
  • Estimate: $0.12
  • Whisper:
  • Surprise %: -525.0%
Apr 25, 2025
Mar 31, 2025 (Pre market)
0.38 Surprise
  • Reported EPS: $2.90
  • Estimate: $2.52
  • Whisper:
  • Surprise %: 15.1%
Feb 04, 2025
Dec 31, 2024 (Pre market)
0.31 Surprise
  • Reported EPS: $0.80
  • Estimate: $0.49
  • Whisper:
  • Surprise %: 63.3%
Oct 25, 2024
Sep 30, 2024 (Pre market)
0.21 Surprise
  • Reported EPS: $1.62
  • Estimate: $1.41
  • Whisper:
  • Surprise %: 14.9%
Jul 26, 2024
Jun 30, 2024 (Pre market)
0.35 Surprise
  • Reported EPS: $2.42
  • Estimate: $2.07
  • Whisper:
  • Surprise %: 16.9%
Apr 26, 2024
Mar 31, 2024 (Pre market)
0.18 Surprise
  • Reported EPS: $2.26
  • Estimate: $2.08
  • Whisper:
  • Surprise %: 8.7%
Feb 06, 2024
Dec 31, 2023 (Pre market)
0.01 Surprise
  • Reported EPS: $0.45
  • Estimate: $0.44
  • Whisper:
  • Surprise %: 2.3%
Oct 24, 2023
Sep 30, 2023 (Pre market)
0.43 Surprise
  • Reported EPS: $2.00
  • Estimate: $1.57
  • Whisper:
  • Surprise %: 27.4%
Jul 28, 2023
Jun 30, 2023 (Pre market)
0.07 Surprise
  • Reported EPS: $2.10
  • Estimate: $2.03
  • Whisper:
  • Surprise %: 3.5%

Financials